Reflections on 10 years of the FDA’s breakthrough therapy designation

被引：0
|
作者：
Asher Mullard
机构：
来源：
Nature Reviews Drug Discovery | 2022年 / 21卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Ellen Sigal, the founder of Friends of Cancer Research, discusses the origins and future of the FDA’s breakthrough therapy designation as well as the changing patient advocacy landscape.
引用
收藏
页码：252 / 253
页数：1
相关论文
共 50 条
  • [41] PARP inhibitor receives FDA breakthrough therapy designation in castration resistant prostate cancer: beyond germline BRCA mutations
    Helleday, T.
    ANNALS OF ONCOLOGY, 2016, 27 (05) : 755 - 757
  • [42] Breakthrough Therapy Designation: Bringing Innovation Swiftly to Patients
    Shah, Arpita
    THERAPEUTIC INNOVATION & REGULATORY SCIENCE, 2015, 49 (02) : 256 - 261
  • [43] Impact of breakthrough therapy designation on cancer drug development
    Michael Shea
    Linda Ostermann
    Ryan Hohman
    Samantha Roberts
    Marina Kozak
    Ryan Dull
    Jeff Allen
    Ellen Sigal
    Nature Reviews Drug Discovery, 2016, 15 : 152 - 152
  • [44] Impact of breakthrough therapy designation on cancer drug development
    Shea, Michael
    Ostermann, Linda
    Hohman, Ryan
    Roberts, Samantha
    Kozak, Marina
    Dull, Ryan
    Allen, Jeff
    Sigal, Ellen
    NATURE REVIEWS DRUG DISCOVERY, 2016, 15 (03) : 152 - 152
  • [45] Expediting Drug Development: FDA's New Regenerative Medicine Advanced Therapy Designation
    Vaggelas, Annegret
    Seimetz, Diane
    THERAPEUTIC INNOVATION & REGULATORY SCIENCE, 2019, 53 (03) : 364 - 373
  • [46] Expediting Drug Development: FDA’s New Regenerative Medicine Advanced Therapy Designation
    Annegret Vaggelas
    Diane Seimetz
    Therapeutic Innovation & Regulatory Science, 2019, 53 : 364 - 373
  • [47] Reflections on DeepSeek's breakthrough
    Poo, Mu-ming
    NATIONAL SCIENCE REVIEW, 2025, 12 (03)
  • [48] Drug Development in Serious Diseases: The New "Breakthrough Therapy" Designation
    Woodcock, J.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2014, 95 (05) : 483 - 485
  • [49] Expedited Programs for Serious Conditions: An Update on Breakthrough Therapy Designation
    Kwok, Martin
    Foster, Theresa
    Steinberg, Michael
    CLINICAL THERAPEUTICS, 2015, 37 (09) : 2104 - 2120
  • [50] MDMA-assisted psychotherapy for PTSD: A promising novel experimental treatment moving into phase 3 trials with FDA breakthrough therapy designation
    Mithoefer, M.
    Mithoefer, A.
    Feduccia, A.
    Jerome, I.
    Wagner, M.
    Hoilland, J.
    Hamilton, S.
    Yazar-Klosinski, B.
    Emerson, A.
    Doblin, R.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2019, 29 : S11 - S12
12345